14.96
전일 마감가:
$15.71
열려 있는:
$15.53
하루 거래량:
554.14K
Relative Volume:
0.35
시가총액:
$111.08M
수익:
-
순이익/손실:
$-121.02M
주가수익비율:
-1.3286
EPS:
-11.26
순현금흐름:
$-114.09M
1주 성능:
-7.37%
1개월 성능:
-35.04%
6개월 성능:
-21.22%
1년 성능:
-97.08%
토닉스 파마슈티컬스 홀딩 Stock (TNXP) Company Profile
명칭
Tonix Pharmaceuticals Holding Corp
전화
212-980-9155
주소
26 MAIN STREET, SUITE 101, CHATHAM, NY
TNXP을(를) 다른 주식과 비교
주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
---|---|---|---|---|---|---|
![]()
TNXP
Tonix Pharmaceuticals Holding Corp
|
14.96 | 111.08M | 0 | -121.02M | -114.09M | -11.26 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
477.52 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
561.49 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
595.70 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
232.75 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beigene Ltd Adr
|
229.22 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
토닉스 파마슈티컬스 홀딩 Stock (TNXP) Upgrades & Downgrades
날짜 | 액션 | 분석자 | 등급 변경 |
---|---|---|---|
2022-04-18 | 개시 | Noble Capital Markets | Outperform |
2019-04-18 | 업그레이드 | ROTH Capital | Neutral → Buy |
2017-08-18 | 업그레이드 | ROTH Capital | Neutral → Buy |
2016-09-07 | 다운그레이드 | ROTH Capital | Buy → Neutral |
2016-02-17 | 재확인 | Oppenheimer | Outperform |
2015-11-04 | 개시 | Cantor Fitzgerald | Buy |
2015-06-12 | 개시 | Oppenheimer | Outperform |
2015-02-17 | 재확인 | ROTH Capital | Buy |
2014-09-29 | 재확인 | ROTH Capital | Buy |
모두보기
토닉스 파마슈티컬스 홀딩 주식(TNXP)의 최신 뉴스
Tonix Pharmaceuticals Announces Oral Presentation And Panel Participation At The World Vaccine Congress Washington 2025 - marketscreener.com
Tonix Pharmaceuticals Announces Oral Presentation and Panel - GlobeNewswire
Major Breakthrough: Tonix Unveils Single-Dose Mpox Vaccine Data at Leading Global Conference - Stock Titan
Why Tonix Pharmaceuticals Corp. (TNXP) Went Down On Thursday? - MSN
Tonix and Makana partner on xenotransplantation research By Investing.com - Investing.com India
Tonix Pharmaceuticals and Makana Therapeutics Announce Collabora - GuruFocus
Tonix and Makana partner on xenotransplantation research - Investing.com
Tonix Pharmaceuticals and Makana Therapeutics Announce - GlobeNewswire
Tonix Pharmaceuticals And Makana Therapeutics Announce Collaboration Combining Tonix'S Anti-Cd40l Monoclonal Antibody (Tnx-1500) With Makana'S Genetically Engineered Organs In Preclinical And Clinical Xenotransplantation Studies - marketscreener.com
Revolutionary Xenotransplantation Breakthrough: Tonix and Makana Join Forces to Combat Organ Failure - Stock Titan
Tonix Pharmaceuticals launches :TONIX ONE™ A digital breakthrough in migraine management - Proactive financial news
Tonix Pharmaceuticals Presented Data and Analyses of TNX-102 SL Treatment Effects on Fibromyalgia at the American Academy of Pain Medicine (AAPM) 2025 Annual Meeting - GlobeNewswire
Game-Changing Fibromyalgia Treatment Achieves Phase 3 Success, FDA Decision Looms - Stock Titan
(TNXP) Investment Analysis - news.stocktradersdaily.com
Peering Into Tonix Pharmaceuticals's Recent Short Interest - Benzinga
TNXP: No AdCom Required for TNX-102 SL NDA… - Yahoo Finance
Tonix Pharmaceuticals to Present at the 2025 Jones Trading Healthcare and Innovation Conference - GlobeNewswire
Tonix Pharmaceuticals Reveals 5 Major Catalysts: FDA Decision, DoD Contract, and Breakthrough Therapies - Stock Titan
Tonix Pharmaceuticals launches migraine management platform By Investing.com - Investing.com South Africa
Tonix Pharmaceuticals Launches TONIX ONE™, a - GlobeNewswire
Tonix Pharma stock rises following TONIX ONE launch By Investing.com - Investing.com South Africa
Tonix Pharma stock rises following TONIX ONE launch - Investing.com Australia
Tonix Pharmaceuticals launches migraine management platform - Investing.com
Tonix Pharmaceuticals Launches TONIX ONE™, a Fully-Integrated Digital Platform Designed to Help Patients Better Understand and Manage Their Migraine Condition - GlobeNewswire
Game-Changing Digital Platform Transforms How Patients Track and Treat Migraines - Stock Titan
Tonix’s Experimental Non-Opioid Analgesic Treatment for Fibromyalgia Could Start Bringing Relief Lat - PharmiWeb.com
Tonix’s Experimental Non-Opioid Analgesic Treatment for Fibromyalgia Could Start Bringing Relief Later This Year - ACCESS Newswire
New to The Street Show #639 Premieres Nationwide on Bloomberg Television, March 29 at 6:30 PM EST Featuring BioVie, Roadzen, Tonix Pharma, and eXoZymes Inc. - Bluefield Daily Telegraph
(TNXP) Long Term Investment Analysis - Stock Traders Daily
Tonix Pharmaceuticals Announces Presentation at the - GlobeNewswire
Fast-Tracked Fibromyalgia Treatment: Tonix Showcases Breakthrough Pain Drug Data Before FDA Decision - StockTitan
2 Stocks Riding the Biotech Surge With Major Catalysts Ahead - Investing.com
Tonix Pharmaceuticals: Potential To Have 'First' New Fibromyalgia Drug In 15 Years - Seeking Alpha
Noble Capital maintains Outperform on Tonix Pharma, $70 target By Investing.com - Investing.com South Africa
Noble Capital maintains Outperform on Tonix Pharma, $70 target - Investing.com
Tonix Pharmaceuticals: FDA AdCom News Positive, But Making Bull Case Is Problematic (TNXP) - Seeking Alpha
Pharma Frenzy: Volatility Ignites Biotech Sector - Benzinga
Top 2 Health Care Stocks That Are Ticking Portfolio Bombs - Benzinga
Tonix advances fibromyalgia drug, eyes Q4 2025 launch By Investing.com - Investing.com Australia
Tonix Pharmaceuticals Says US FDA Will Not Require Committee Meeting to Discuss NDA for Fibromyalgia Treatment; Shares Up - MarketScreener
Tonix advances fibromyalgia drug, eyes Q4 2025 launch - Investing.com India
Tonix Pharmaceuticals Says US FDA Will Not Require Committee Meeting to Discuss NDA for Fibromyalgia Treatment - Marketscreener.com
Tonix Pharmaceuticals stock soars on FDA update By Investing.com - Investing.com Australia
Tonix Pharmaceuticals stock soars on FDA update - Investing.com
Tonix Pharma’s TNX-102 SL Advances in FDA Process - TipRanks
Tonix Pharmaceuticals Announces that FDA Will Not Require - GlobeNewswire
First New Fibromyalgia Treatment in 15 Years Advances: FDA Expedites TNX-102 SL Review - Stock Titan
Tonix Pharmaceuticals Stock Dives After Q4 Earnings Miss, But Retail’s Feeling Bullish - MSN
As Mpox Cases Spread Around the World, Tonix Pharmaceuticals’ Single-Dose Vaccine TNX-801 Has Potential to Slow the Spread - BioSpace
토닉스 파마슈티컬스 홀딩 (TNXP) 재무 분석
매출
순이익
현금흐름
주당 순 이익
자본화:
|
볼륨(24시간):